Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Biopharmaceuticals

Investors claim in a federal class action that revelations about the efficacy of the macular-degeneration therapy Fovista, as well as the likelihood of FDA approval, caused Ophthotech’s stock to drop 86 percent, from $38.88 to $5.29 per share, in one day of trading last month.

MANHATTAN – Investors claim in a federal class action that revelations about the efficacy of the macular-degeneration therapy Fovista, as well as the likelihood of FDA approval, caused Ophthotech’s stock to drop 86 percent, from $38.88 to $5.29 per share, in one day of trading last month.

Follow @bleonardcns
Categories / Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...